Cargando…
Cost-effectiveness of adjuvant chemotherapy for curatively resected gastric cancer with S-1
BACKGROUND: The effectiveness of specific regimens of adjuvant therapy for gastric cancer has not been verified by large clinical trials. Recently, several large trials attempted to verify the effectiveness of adjuvant therapy. The Adjuvant Chemotherapy Trial of TS-1 for Gastric Cancer in Japan, a r...
Autores principales: | Hisashige, Akinori, Sasako, Mitsuru, Nakajima, Toshifusa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3816158/ https://www.ncbi.nlm.nih.gov/pubmed/24079752 http://dx.doi.org/10.1186/1471-2407-13-443 |
Ejemplares similares
-
Cost-effectiveness of adjuvant chemotherapy with uracil–tegafur for curatively resected stage III rectal cancer
por: Hisashige, A, et al.
Publicado: (2008) -
Survival after recurrence in patients with gastric cancer who receive S-1 adjuvant chemotherapy: exploratory analysis of the ACTS-GC trial
por: Ito, Seiji, et al.
Publicado: (2018) -
Association between adjuvant chemotherapy and survival in stage I gastric cancer patients after curative resection
por: Chen, Qiuying, et al.
Publicado: (2023) -
Adjuvant chemotherapy in curatively resected rectal cancer: How valid are the data?
por: Manzini, Giulia, et al.
Publicado: (2020) -
Update of Adjuvant Chemotherapy for Resected Gastric Cancer
por: Oh, Sang Cheul
Publicado: (2012)